Abetimus
 | |
| Clinical data | |
|---|---|
| Trade names | Riquent |
| ATC code | |
| Identifiers | |
| CAS Number | |
| PubChem SID | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C1632H1944N610Na156O970P156S4 |
| Molar mass | 54171.35 g·mol−1 |
  (what is this?) | |
Abetimus (trade name Riquent) is an immunosuppressant.[1] It is a synthetic biological called a tolerogen. It is made of four double-stranded oligodeoxyribonucleotides that are attached to a carrier platform and are designed to block specific B-cell anti double stranded DNA antibodies.[2] It may also complex anti dsDNA antibodies together, therefore disabling them. This way abetimus was supposed to help treat systemic lupus erythematosus and specifically lupus nephritis.
It was developed by , who applied for marketing authorisations in the mid-2000s, but the drug was never marketed in the US or in Europe.[3][4]
References[]
- ^ "Abetimus: Abetimus sodium, LJP 394". BioDrugs. Springer Nature Switzerland AG. 17 (3): 212–5. 2003. doi:10.2165/00063030-200317030-00009. PMID 12749759. S2CID 19896886.
- ^ Wallace DJ (January 2001). "Clinical and pharmacological experience with LJP-394". Expert Opinion on Investigational Drugs. Informa. 10 (1): 111–7. doi:10.1517/13543784.10.1.111. PMID 11116284. S2CID 43518002.
- ^ "Riquent Approval Status". Drugs.com. Retrieved 7 January 2017.
- ^ "Riquent". European Medicines Agency. Retrieved 7 January 2017.
 | This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by . |
Categories:
- Immunosuppressants
- Antineoplastic and immunomodulating drug stubs